Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (22091)	6/13/1998 5:15:00 PM
From: WTDEC	Respond to of 32384

Richard, as you may know, Bill Respess, VP and General Counsel at LGND was a Patent Attorney at Lyon & Lyon prior to joining LGND and LGND works extensively with L & L. While at the San Diego biotech meetings HN refers to, I had a chance to spend about a hour with a senior L & L Patent Attorney. As you would expect, I was unable to pry lose any specific information but it was clear that LGND had them swamped with work. Finally, I was able to discuss the Roche patent infringement matter with DR in some detail. I came away quite comfortable with LGND's general patent strategy. Further, I surmise that many patents are being filed which is consistent with HN's comments. Given the other anecdotal information that LGND has been pouring resources into the area and that SKB is grabbing molecules, it is plausible to infer that the answer to your good question: "how many practiced examples, receptors and chemistries, will they have to support claim one in the CIP? " will also be good. Time, of course, will reveal the actual facts. Regards, Walter PS: Thanks for your thoughtful posts.